RJA
PFE icon

Raymond James & Associates’s Pfizer PFE Stock Holding History

Raymond James & Associates’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,900
Closed -$725K – 4005
2023
Q4 		$725K Buy
+24,900
New +$753K ﹤0.01% 2718
2023
Q3 		– Sell
-13,600
Closed -$544K – 3902
2023
Q2 		$544K Buy
+13,600
New +$529K ﹤0.01% 2888

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Raymond James & Associates's PFE Position: Q3 2024 in Review

Raymond James & Associates reduced its Pfizer (PFE) stake by 4.1% in Q3 2024, selling an estimated $10.2M and leaving 8,209,415 shares worth $238M. The position accounts for 0.14% of the portfolio, ranked #123.

Raymond James & Associates first reported a position in PFE in Q2 2013 and has held it in 46 quarters since. The position peaked at $564M in Q4 2019. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

  • Raymond James & Associates held 8,209,415 shares of Pfizer worth $238M as of Q3 2024.
  • Raymond James & Associates sold 349,305 Pfizer shares in Q3 2024, an estimated $10.2M.
  • Pfizer made up 0.14% of Raymond James & Associates's portfolio in Q3 2024, its #123 holding.
  • Raymond James & Associates first reported a position in Pfizer in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Pfizer position peaked at $564M in Q4 2019.
  • 2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.